Nutra Pharma Corporation (OTCQB: NPHC) subsidiary Designer
Diagnostics focuses its energy on designing and developing medical devices.
Established in 2005, the company builds shareholder value by marketing and
selling rapid diagnostics test kits for infectious diseases such as
tuberculosis (TB) and nontuberculous mycobacteria (NTM).
Designer Diagnostics test kits deliver cost effective and
efficient, low infrastructure solutions for identifying and testing the
sensitivity of NTM that have the ability to utilize paraffin wax as a sole
carbon source or those that are hydrophobic. Designer Diagnostics also delivers
an efficient solution for the rapid identification and sensitivity testing of
TB.
Designer Diagnostic’s test kits offer many benefits, such as
the ability to provide diagnosis in less than seven days. Other attractive
characteristics include long shelf life; ability to be stored in extremely
hostile environments; cost effectiveness, as compared to most other traditional
methods; and they do not require new large capital expenditures, just to name a
few.
Recently, Nutra Pharma Corporation released a letter to
shareholders. The letter, delivered by Rik J. Deitsch, the company’s chief
executive officer, gave investors a brief overview of Nutra Pharma’s progress
during 2015, as well as its goals and expectations for the coming months.
“We have had a very busy year at Nutra Pharma,” Deitsch
explained in the news release. “2015 has been an inflection year for the
company, launching our first new product in over two years (Pet Pain-Away),
allowing us to begin to get back into clinical research on our lead drug
candidates and bringing our drug platform into focus with the granting of
orphan designation for RPI-78M for the treatment of pediatric multiple sclerosis.”
Looked upon as some of the most intriguing news for
potential investors was the company’s progress with its therapeutic drug
pipeline. In September, the company received orphan status for drug candidate
RPI-78M for the treatment of pediatric multiple sclerosis, an indication with
no approved treatments currently on the market. Additionally, NPHC continues to
make progress toward expanding its retail distribution network for its
over-the-counter products. Sales from Nyloxin and Pet Pain-Away are promising
revenue streams for the company that are viewed as being vital to the financing
of proposed clinical studies.
For more information on the company, visit
www.NutraPharma.com
About QualityStocks
QualityStocks
is committed to connecting subscribers with companies that have huge potential
to succeed in the short and long-term future. We offer several ways for
investors to find, evaluate, and learn more about investing in these companies.
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment